Kostas Galanis

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.

M. Buti, T. Berg, R. Idilman, 2020, Journal of hepatology.

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.

M. Buti, T. Berg, R. Idilman, 2020, Journal of hepatology.

Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

M. Buti, R. Idilman, C. Yurdaydın, 2021, JHEP reports : innovation in hepatology.

P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC)

M. Buti, R. Idilman, C. Yurdaydın, 2015 .

P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF)

R. Idilman, C. Yurdaydın, P. Lampertico, 2014 .

Nursing Assessment and Management of Pain in Infants

Kostas Galanis, Jennifer Kostiander, 2016 .